NASDAQ: ACRSAclaris Therapeutics Inc Stock
$4.50+0.08 (+1.81%)
Updated Jun 18, 2026
ACRS Price
$4.50
Fair Value Price
-$0.95
Market Cap
$628.49M
52 Week Low
$1.34
52 Week High
$5.15
P/E
-8.04x
P/B
4.38x
P/S
57.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.37M
Earnings
-$69.66M
Gross Margin
9.7%
Operating Margin
-832.58%
Profit Margin
-832.6%
Debt to Equity
0.38
Operating Cash Flow
-$52M
Beta
1.03
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ACRS Overview
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACRS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
ACRS
Ranked#36 of 44
Ranked#36 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $26.18 | A | |
| $127.06 | B | |
| $105.15 | B |
Be the first to know about important ACRS news, forecast changes, insider trades & much more!
ACRS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACRS ($4.50) is overvalued by 574.39% relative to our estimate of its Fair Value price of -$0.95 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACRS ($4.50) is not significantly undervalued (574.39%) relative to our estimate of its Fair Value price of -$0.95 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACRS due diligence checks available for Premium users.
Valuation
ACRS fair value
Fair Value of ACRS stock based on Discounted Cash Flow (DCF)
Price
$4.50
Fair Value
-$0.95
Undervalued by
574.39%
ACRS ($4.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACRS ($4.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACRS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.04x
Industry
14.73x
Market
9.47x
ACRS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.38x
Industry
3.48x
ACRS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACRS's financial health
Profit margin
Revenue
$2.0M
Net Income
-$19.8M
Profit Margin
-993.2%
ACRS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ACRS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$198.7M
Liabilities
$55.1M
Debt to equity
0.38
ACRS's short-term assets ($110.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACRS's short-term assets ($110.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACRS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ACRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.1M
Investing
-$30.9M
Financing
$57.8M
ACRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACRS vs Diagnostic & Research Stocks
Aclaris Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.